← Evidence map

ArticleEuropean journal of neurology2026

Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis.

Leonardo Palazzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis. | OpenQuestion